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Abstract 
A characteristic of the antioxidant, probucol, is its inability to inhibit apolipoprotein B fragmentation in low density lipoprotein (LDL), despite 
a pronounced ability to inhibit lipid oxidation on relatively lengthy exposure to Cu(lI). Here we show that a short exposure of LDL to hydrogen 
peroxide and Cu(I1) leads to ‘251-labelled apolipoprotein B fragmentation, the production of malondialdehyde and hydroperoxides and leads to 
increased uptake by macrophages on subsequent culture. However, pre-loading LDL with probucol protects LDL from lipid oxidation but not protein 
fragmentation or macrophage uptake. The use of probucol to conduct studies on apolipoprotein B oxidation without extensive lipid oxidation may 
prove useful when studying LDL apolipoprotein damage on exposure to an aqueous free radical insult. 
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1. Introduction 
There is now substantial evidence in favour of low 
density lipoprotein (LDL) oxidation playing a role in the 
development of atherosclerosis [1,2]. A major source of 
lipid in the lesion is thought to be oxidatively modified 
LDL, which has been detected in lesions using immu- 
nohistochemistry [3]. Studies in animal models of the 
disease have shown antioxidants to be protective and this 
is supported by some human epidemiological studies 
[&6]. However, the cause of oxidation of LDL remains 
uncertain. One possible factor is the availability of tran- 
sition metals as catalysts for such oxidative events [7]. 
However, transition metal availability has, thus far, been 
shown only in very advanced lesions [7] and may partic- 
ipate only in later stages of lesion development rather 
than lesion initiation. 
Many in vitro studies suggest that macrophages play 
a role in LDL oxidation, possibly involving the respira- 
tory burst [8,9] and cystine metabolism [lO,l 11. Many 
other cell-independent alternatives have been proposed, 
including autoxidation of ascorbate [ 121 and glucose [ 131. 
For instance, there is some evidence that in diabetes 
mellitus, in which the severity of atherosclerosis is ele- 
vated, ascorbic acid levels are reduced and its oxidised 
product, dehydroascorbate, is increased [14]. This sug- 
gests that ascorbic acid oxidation occurs, with its con- 
comitant production of aldehydes, superoxide, hydrogen 
peroxide and hydroxyl radicals [15,16]. There is also 
some suggestion that glucose, via its ability to generate 
oxidants of a similar hydrophilic nature, may contribute 
to oxidative stress and the complications of diabetes [ 171. 
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However, one factor common to many, if not all propos- 
als is the formation of an initiating free radical species 
of a hydrophilic nature within an aqueous environment. 
The lipid content of LDL, as opposed to the protein 
content, is protected by lipophilic antioxidants such as 
vitamin E [ 181 which, physiologically, appear to be main- 
tained in the reduced form by such aqueous reducing 
agents as ascorbic acid [18]. Should the initiating species 
causing LDL oxidation in vivo prove to be predomi- 
nantly in the aqueous phase then the study of damage to 
apolipoprotein B by such oxidising species may prove to 
be of importance. The current emphasis on developing 
an interventional approach based upon the interruption 
of oxidative reactions might therefore have to take such 
an effect into account. 
Probucol, 4,4’-(isopropylidenedithio)bis[2,6-di-terl- 
butylphenol], has a structural similarity to butylated hy- 
droxytoluene and is known to inhibit LDL lipid peroxi- 
dation in vitro and LDL uptake and degradation in 
Watanabe hereditary hyperlipidaemic rabbits [ 191. Inde- 
pendent of any of its hypocholesterolaemic effect, pro- 
bucol has also been shown to inhibit the progression of 
atherosclerosis in Watanabe rabbits [ 19,201. However, 
there has been some suggestion that probucol cannot 
lower arterial coverage of thoracic aortic lesions in rab- 
bits [20] and that its effects are rather more complicated; 
the anti-atherosclerotic effect of probucol has also been 
shown to differ when comparing the rates of animal 
growth [21]. That probucol is unable to reduce lesion 
coverage whilst reducing cholesteryl ester content of le- 
sions [20] might be taken to imply that probucol has little 
effect upon the initiating cause of atherogenesis. Thus, 
given the extremely lipophilic nature of probucol, these 
observations might be consistent with an initiating oxi- 
dative process of an aqueous origin. The preservation of 
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endogenous antioxidants in LDL by ascorbic acid, but 
not probucol [22], during LDL oxidation suggests that 
the inability of probucol to decrease lesion coverage con- 
sistently in the rabbit model of atherosclerosis is related 
to its inability to ‘link’ with aqueous antioxidants and to 
scavenge oxidising species in the aqueous milieu. 
Using probucol, it is possible to fragment apolipopro- 
tein B in LDL oxidatively with only a limited extent of 
lipid oxidation [23]. We have therefore investigated the 
possibility that protein oxidation, monitored by frag- 
mentation, affects LDL uptake by macrophages in a 
manner that is independent of lipid oxidation. 
2. Experimental 
Radiochemicals were obtained from Amersham (Aylesbury, UK). 
All biochemicals were obtained from Sigma (Poole, UK) or Aldrich 
(Gillingham, UK) unless stated otherwise and were of the highest purity 
available. 
Human low density lipoprotein (LDL) was prepared from normal 
individuals as previously described [I 3,231. Briefly, blood from healthy 
volunteers was centrifuged in the presence of 1 mg/ml EDTA to obtain 
plasma. Lipid fractions were obtained from pooled plasma by ultracen- 
trifugation and flotation through potassium bromide gradients. Cen- 
trifugations were performed at 100,000 x g for 18 h at 4°C in the 
presence of EDTA. Low density lipoprotein (LDL) was taken as the 
fraction that floated at a relative density of 1.063 g/ml. Prior to exper- 
imentation, LDL was dialysed overnight at 4°C against phosphate- 
buffered saline containing chelating resin (Sigma) to remove any EDTA 
and transition metals. 
Pre-loading of LDL with probucol was performed as previously 
described [24]. Essentially, radioiodinated LDL (3.5 mg/ml) was incu- 
bated at 37°C for 2 h with no further additions, 100 PM probucol in 
ethanol (0.1% v/v in incubation) or with ethanol alone. The LDL was 
then subjected to sieve chromatography (PDIO columns) to remove 
LDL-unassociated ethanol or probucol. 
LDL (2.5 mg/ml) was then incubated with 2.5 mM hydrogen perox- 
ide and 50 PM Cu(I1) for 3 h at 37°C in the presence of IO mM 
potassium phosphate (pH 7.4). At various times throughout this expo- 
sure to an aqueous free radical generating system, samples were re- 
moved and treated with 200 IU catalase and chelating resin for 10 min. 
Samples were then immediately assessed for thiobarbituric acid-reac- 
tive material (malondialdehyde equivalents) [13,23,25], hydroperoxide 
content as measured by the xylenol orange assay [13,23,25]. Fragmen- 
tation of apolipoprotein B was determined by measuring peptides solu- 
ble in 5% trichloroacetic acid (TCA), as previously described 1261. 
Samples were retained for cell uptake studies using-P388Dl macro- 
phage-like cells and also for sodium dodecyl sulphate polyacrylamide 
gel electrophoresis (SDS-PAGE) [27,28] and analysis of electrophoretic 
mobility on agarose gels using a CIBA-Corning system. The uptake of 
such pre-incubated [“‘I]LDL by P388Dls on culturing with 100 &ml 
LDL for 5 h was determined as previously described [23]. Uptake of 
LDL in cells is expressed as ng LDL/mg cell protein, the later assessed 
by the Lowry assay for protein [29]. 
Cell culture of the P388Dl macrophage cell line was conducted as 
previously described at 37°C with an’atmosphere of 5% CO, and 95% 
air 1301. The cells were maintained in Dulbecco’s Modified Eagles Me- 
dium and 10% foetal calf serum [30]. Cells were plated at 0.5 x lo6 
cells/ml in 24-well plates and cultured for 5 h (LDL studies) or in 3 ml 
plates for 24 h cultures (BSA studies). 
3. Results and discussion 
During these studies we have used P388Dl cells, a 
macrophage-like cell line derived from a lymphoid neo- 
plasm of DBAM mice treated with 3-methylcholan- 
threne. This cell line has been shown to bind and degrade 
native and modified LDL in a manner analogous to that 
of murine peritoneal macrophages and human periph- 
eral blood monocyte-derived macrophages [29]. 
The exposure of 2.5 mg/ml human LDL to 2.5 mM 
hydrogen peroxide and 50 PM Cu(I1) over 3 h leads to 
the accumulation of thiobarbituric acid-reactive material 
(expressed as malondialdehyde equivalents) (Fig. 1 A), 
and the formation of lipid hydroperoxides (Fig. lB), 
detectable by the Xylenol orange assay. When LDL was 
pre-loaded with probucol (with ethanol as a carrier) 
there was a marked decrease in both parameters of lipid 
peroxidation. A control of LDL incubated with Cu(I1) 
alone showed negligible levels of lipid oxidation beyond 
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Fig. I. LDL was oxidised as described in the text and assessed for 
(A) thiobarbituric acid-reactive material (expressed as malondialde- 
hyde equivalents) and (B) lipid hydroperoxides detectable by the Xyle- 
nol orange assay. Values are expressed as the mean + S.D. obtained 
from triplicate experiments. In this and all other figures: Cu(Il) = ex- 
posed to Cu(I1) alone; HOOH = exposed to H202/Cu(II); Ethanol/ 
HOOH = pretreated with ethanol and exposed to HZO,/Cu(II); Probu- 
col/HOOH = pre-loaded with probucol (in ethanol) and exposed to 
HZO,/Cu(lI). 
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Fig. 2. Apolipoprotein B fragmentation to TCA-soluble radiolabelled 
fragments was determined. Values are expressed as mean f SD. ob- 
tained from quadruplicate assays within a representative experiment. 
the baseline when monitored by the thiobarbituric acid 
assay. When monitored by the Xylenol orange assay, 
however, there was a modest increase in lipid hydroper- 
oxides, in keeping with the known pro-oxidant activity 
of Cu(I1) with LDL. Another control of LDL pre-loaded 
with ethanol alone did not exhibit any difference in sus- 
ceptibility to oxidation by the H,O,/Cu(II) free radical 
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generating system used in these studies. Thus, the extent 
of lipid peroxidation of LDL exposed to Cu(I1) alone or 
LDL pre-loaded with probucol and exposed to H,O,/Cu 
appears to remain within a ‘lag period’ over this short 
term exposure. After 24 h exposure, lipid peroxidation 
was unaffected by any of the conditions used within these 
studies and approached the high levels of peroxide accu- 
mulation previously described [25]. 
Fig. 2 shows the effect of the H,O,/Cu(II) oxidising 
system upon apolipoprotein B integrity. Apolipoprotein 
B is the sole protein of LDL and is the site of radioiodi- 
nation. During exposure to the aqueous oxidising system 
used in these studies the protein is fragmented to TCA- 
soluble radiolabelled peptides. Like the parameters of 
lipid peroxidation (Fig. l), protein fragmentation occurs 
in a time-dependent manner. However, fragmentation 
differs from lipid peroxidation in that it is not limited by 
pre-loading LDL with probucol. There were no differ- 
ences in apolipoprotein fragmentation of LDL with or 
without pre-loading with probucol (ethanol as a carrier) 
or ethanol. LDL which was incubated with Cu(I1) alone 
showed some fragmentation, expected given the accumu- 
lation of some peroxide shown in Fig. 2 and the ability 
of lipid peroxide and Cu(I1) to fragment protein [27]. 
These observations were confirmed on analysis by 
SDS-PAGE (Fig. 3) which again showed no inhibitory 
effect of probucol on fragmentation of apolipoprotein B. 
Interestingly, SDS-PAGE of treated LDL shows no gen- 
eration of distinct peptide fragments but an increase in 
peptides present in LDL exposed to Cu(I1) alone, as well 
as buffer alone (not shown), and the formation of ran- 
domly sized fragments, giving the appearance of a 
‘smear’. This is unlike SDS-PAGE analysis of other pro- 
teins exposed under similar conditions, which shows the 
formation of distinct peptides [27], becoming a ‘smear’ 
only after very extensive oxidation. The presence of 
small peptides in LDL exposed to Cu(I1) and buffer 
alone over such a short period, an increase in their den- 
sity and the obvious generation of peptides of a random 
size on exposure to H,O,/Cu(II) suggest that polipopro- 
MW 5 6 7 
Fig. 3. Apolipoprotein B fragmentanon was visualised by SDS-PAGE, using a 10% polyacrylamide [23,24] gel and staining with silver nitrate. 
MW = molecular weight markers of 97.4, 66.2 and 45.2 kDa, respectively. Lanes 1 and 2 = LDL exposed to Cu(II) alone for 0 and 4 h, respectively. 
Lanes 3 and 4 = LDL exposed to H,O,/Cu for 0 and 4 h, respectively. Lanes 5, 6 and 7 = probucol loaded LDL exposed to H,O,/Cu for 0, 2 and 
4 h, respectively. 
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Fig. 4. The uptake of [‘251]LDL was monitored in P388Dls. Values are 
expressed as mean ? SD. obtained from quadruplicate assays within 
a representative experiment. 
tein B is all too readily oxidised [31]. Changes in electro- 
phoretic mobility on agarose electrophoresis were slight 
and least apparent for probucol-loaded LDL exposed to 
H,O,/Cu(II) (not shown). This later observation is in 
keeping with the relatively low levels of lipid oxidation 
(Fig. l), and also a limited subsequent apolipoprotein B 
aldehydic modification (a process dependent on concen- 
tration of aldehyde and time of exposure), that occurred 
during the short times of exposure to H,O,/Cu(II) used 
throughout these studies. 
The uptake of LDL after exposure to the aqueous 
oxidising system used in these studies (Fig. 4) best re- 
flected the changes observed on monitoring apolipopro- 
tein B fragmentation, rather than the parameters of lipid 
oxidation shown in Fig. 1A and B. Thus, whereas probu- 
co1 inhibited parameters of lipid peroxidation, it had no 
effect upon apolipoprotein B oxidation or subsequent 
uptake by P388Dl s. Although lipid peroxidation and its 
subsequent aldehydic forms of apolipoprotein B modifi- 
cation have been shown to increase LDL uptake by 
P388Dls, via scavenger receptors [30], it would also ap- 
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pear that oxidative apolipoprotein B fragmentation is 
also associated with LDL uptake. Whether uptake of 
oxidised protein involves the scavenger receptor in 
P388Dl cells remains unclear, as does the relative impor- 
tance of macrophage scavenger receptors in the lesions 
themselves [32-341. It is possible that phagocytic activity 
plays a greater role in foam cell formation than any one 
specific receptor-mediated uptake [32-341. Thus, 
whether the uptake of oxidised protein involves the scav- 
enger receptor may not be highly relevant. However, 
P388Dl cells possess receptors for both native and mod- 
ified LDL [31] and it is possible that minimally oxidised 
LDL (produced during these studies) is taken up via the 
native receptor [35]. On the other hand, there is little 
evidence in favour of increased uptake by this receptor 
on oxidation of apolipoprotein B. Generally, apolipo- 
protein B modification results in a decreased uptake by 
the native receptor [36,37]. 
The relative importance of whether protein oxidation 
aloone contributes to cell uptake is likely to depend on 
the initiating cause of LDL oxidation and the relative 
ease with which it is oxidised. For instance, recent re- 
ports suggest that hypochlorite, a powerful oxidant, can 
oxidatively damage apolipoprotein B and transform 
LDL to a high-uptake form for macrophages, without 
the necessity of extensive lipid oxidation or antioxidant 
depletion [38]. Our observations suggest that if the initi- 
ating cause of LDL oxidation in vivo takes the form of 
an aqueous free radical insult then there is the possibility 
that protein oxidation occurs first, leading to LDL up- 
take in the first stages of foam cell formation and athero- 
genesis. Perhaps lipid oxidation and accompanying alde- 
hydic modification is pertinent to later stages of lesion 
development rather than earlier stages of atherogenesis. 
The inability of probucol to protect protein from oxida- 
tive damage, unlike DL-a-tocopherol shown in previous 
studies [23], makes it possible to study apolipoprotein 
oxidation independent of lipid peroxidation. This, in it- 
self, makes LDL pre-loading with probucol, and perhaps 
other extremely lipophilic antioxidants, a useful experi- 
mental approach. 
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